Online inquiry

IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4215MR)

This product GTTS-WQ4215MR is a type of mRNA modified with 5-Methyl-CTP, which ecodes the monoclonal antibody that targets Factor IX substitute gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000133.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2158
UniProt ID P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ4215MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10140MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LBR-101
GTTS-WQ14376MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ9515MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA J-591
GTTS-WQ14216MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG4934
GTTS-WQ3718MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ15763MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ6286MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ4896MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BYM338
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW